Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

News

Hepatitis B and CML survey extended for one more week! – Deadline April 24th

HepatitisBwebsitebannerApril 2024 - Thank you to everyone who shared their experiences in the iCMLf Hepatitis B Virus (HBV) and CML Screening and Management Survey.

Your contributions are essential to improving the understanding and management of Hepatitis B for people living with CML. This global collaboration - and the insights gained from your clinical practice - bring us one step closer to informing future recommendations and enhancing patient care.

Submissions are now open until April 24th to help close regional data gaps.

Second pediatric CML case review: TFR after 9 years on imatinib without prior DMR

2nd pediatric caseApril 2025 - We are pleased to share the second publication in our ongoing series of pediatric CML (pCML) case reviews from low and middle-income countries (LMICs). These cases reflect the complexities inherent in managing pCML in resource-limited settings and aim to provide a comprehensive discussion from various perspectives to enhance knowledge and improve patient outcomes.

The latest case, published in the March edition of Case Reports in Oncology Medicine, highlights a challenging case from Brazil. Experts discuss treatment discontinuation in a child with CML who has not achieved a sustained deep molecular response.

Recognising excellence in CML - Congratulations to the 2025 iCMLf prize winners

2025 iCMLf Prize winnersMarch 2025 - Every year, the iCMLf Prizes acknowledge individuals whose remarkable contributions have shaped the field of CML, driving progress in research, treatment, and care worldwide. This year, we celebrate three outstanding people whose work has transformed our understanding of CML biology, refined clinical management, and improved CML treatment and care in low- and middle-income countries.

We are delighted to announce the recipients of the 2025 iCMLf Prizes:

  • Rowley Prize – Professor Satu Mustjoki (Finland)
  • Goldman Prize – Dr. Delphine Rea (France)
  • iCMLf Prize – Professor Nicholas Anthony Othieno-Abinya (Kenya)

25 Years of TKIs: A Timeline of Transformation


TKIs logo ideasTwenty-five years ago, the landscape of chronic myeloid leukemia (CML) treatment changed forever with the introduction of tyrosine kinase inhibitors (TKIs). Before this breakthrough, CML was a life-threatening diagnosis, with limited treatment options such as interferon therapy or bone marrow transplantation. Today, thanks to TKIs, CML has transformed into a manageable condition, allowing patients to live full and productive lives.

Register Now: iCMLf Regional Discussion Groups - South Asia 2025

We are pleased to announce the first instalment of our 2025 South Asian regional program to address specific local challenges for physicians treating people with CML. We are starting this year's progam of three zoom-based Regional Discussion Groups on April 23rd.

Register Now: iCMLf Regional Discussion Groups - Latin America 2025

We are pleased to announce the first instalment of our 2025 Latin American regional program to address specific local challenges for physicians treating people with CML. We are starting this year's progam of three zoom-based Regional Discussion Groups on May 8th.